ERAS-4001 for Cancer
(BOREALIS-1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines a new treatment called ERAS-4001, an experimental therapy, to determine its safety for individuals with advanced or metastatic solid tumors that have specific KRAS mutations. The treatment will be tested alone and in combination with other new medicines. Suitable candidates have solid tumors with specific mutations and lack other effective standard treatments. Participants must be able to take pills and agree to follow the study rules. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Earlier research showed that ERAS-4001 had promising results in the lab against certain cancer mutations. This suggests potential effectiveness, but its safety in humans is still under investigation. As a Phase 1 trial, the primary goal is to determine the safety of ERAS-4001 and how the body processes it. Phase 1 trials mark the first time a new treatment is tested in people, so limited safety information is available. Researchers are testing the treatment both alone and with another drug, closely monitoring patient responses to different doses. This will help determine if ERAS-4001 is well-tolerated and identify any potential side effects.12345
Why are researchers excited about this trial's treatments?
Unlike the standard of care for cancer, which often includes chemotherapy and radiation, ERAS-4001 is administered orally and features a new mechanism of action. Most cancer treatments work by attacking rapidly dividing cells, but ERAS-4001 is designed to target specific cancer cell pathways, potentially offering a more precise treatment option. Researchers are excited about ERAS-4001 because it can be used both as a standalone treatment and in combination with other investigational agents, providing flexibility in addressing different types of tumors. This targeted approach could minimize side effects and improve outcomes for patients.
What evidence suggests that ERAS-4001 could be an effective treatment for advanced or metastatic solid tumors?
Research shows that ERAS-4001 targets KRAS mutations, which are changes in a gene linked to cancer growth. Early lab studies have demonstrated its strong potential by effectively blocking both active and inactive forms of KRAS, even at very low doses. This suggests it could be quite effective against tumors with these mutations. It did not affect other similar proteins, which might help reduce side effects. In this trial, participants may receive ERAS-4001 as a monotherapy or in combination with another investigational agent. When combined with other treatments, ERAS-4001 aims to increase effectiveness by working alongside existing therapies. Overall, early findings are promising for its use in treating certain advanced cancers.12467
Who Is on the Research Team?
Gerri Lee
Principal Investigator
Erasca, Inc.
Are You a Good Fit for This Trial?
This trial is for patients with advanced or metastatic solid tumors that have specific KRAS mutations. Details on eligibility criteria are not fully provided, but typically include factors like age, health status, and previous treatments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Optimization
Dose optimization of ERAS-4001 monotherapy and in combination with other cancer therapies
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ERAS-4001
Find a Clinic Near You
Who Is Running the Clinical Trial?
Erasca, Inc.
Lead Sponsor